ORM2 Regulates Pancreatic Fibrosis via ZG16-Mediated Autophagy Control

Study Background and Research Question

Chronic pancreatitis (CP) is a progressive fibro-inflammatory disorder characterized by irreversible damage to the pancreas, leading to persistent pain and loss of both exocrine and endocrine function. Central to CP pathogenesis is pancreatic fibrosis, driven by the activation of pancreatic stellate cells (PSCs), which secrete excessive extracellular matrix (ECM) proteins. Despite advances in the management of CP, there are still no effective therapies that target or reverse fibrotic progression. Recent research has illuminated the role of autophagy—a regulated process of lysosomal degradation—in PSC activation and subsequent fibrosis. However, the upstream molecular regulators controlling this process remained insufficiently characterized. The present study addresses whether ORM2, an acute-phase protein previously implicated in inflammation and tissue remodeling, modulates pancreatic fibrosis in CP by affecting autophagy in PSCs.

Key Innovation from the Reference Study

The study provides a significant advance by identifying ORM2 as a negative regulator of PSC activation and pancreatic fibrosis, acting through direct interaction with ZG16 to suppress autophagic flux. This mechanistic insight not only clarifies how autophagy is regulated in fibrotic progression but also highlights ORM2 as a promising molecular target for antifibrotic intervention. The discovery that ZG16 is necessary for ORM2's antifibrotic effects delineates a specific regulatory axis that can be leveraged in future therapeutic strategies. This work is thus a pivotal contribution to the understanding of tissue remodeling in pancreatic disease (reference study).

Methods and Experimental Design Insights

The researchers used a robust combination of in vivo and in vitro models. Chronic pancreatitis was induced in mice via repeated injections of caerulein (ceruletide), establishing a well-validated model for studying pancreatic fibrosis and PSC biology. Pancreas-specific ORM2 knockout and overexpression were achieved using adeno-associated virus (AAV)-mediated gene delivery. Fibrotic activation in human and mouse PSCs was modeled by TGF-β1 stimulation. Autophagic activity was probed using Western blot analysis for LC3B and p62, transmission electron microscopy for autophagosome quantification, and LC3B-RFP-GFP reporter assays to monitor autophagic flux. To uncover the mechanistic axis, the study employed SPIDER protein-interaction mapping and co-immunoprecipitation, identifying ZG16 as the binding partner mediating ORM2's effects.

Protocol Parameters

• Induction of CP: Caerulein (ceruletide) 50 μg/kg, intraperitoneally, administered 6 times/day for 6 weeks to induce chronic pancreatic injury and fibrosis.
• ORM2 modulation: AAV-mediated pancreas-specific knockout or overexpression; viral vectors delivered 2 weeks prior to caerulein administration.
• PSC activation in vitro: Human or mouse PSCs treated with 2 ng/mL TGF-β1 for 24–48 h.
• Autophagy assays: LC3B-RFP-GFP tandem reporter transfection, followed by confocal imaging; Western blot for LC3B-II/I and p62 levels; transmission electron microscopy for autophagosome/autolysosome quantification.
• Protein interaction validation: SPIDER and co-immunoprecipitation protocols for ORM2-ZG16 binding characterization.

Core Findings and Why They Matter

ORM2 was significantly downregulated in pancreatic tissue during CP but elevated in serum and liver, suggesting organ-specific regulatory dynamics. Pancreas-specific deletion of ORM2 in mice exacerbated fibrotic changes, evidenced by increased expression of α-SMA, COL1A1, and fibronectin, and by enhanced collagen deposition. Conversely, ORM2 overexpression mitigated these fibrotic markers and preserved pancreatic architecture. Mechanistic experiments demonstrated that ORM2 inhibits autophagy at the stage of autolysosome formation, which in turn suppresses PSC activation and ECM production. Critically, SPIDER and co-IP analyses confirmed that ORM2 binds ZG16, and genetic deletion of ZG16 abolished ORM2's antifibrotic effects in both mouse and cell models. These results position ORM2-ZG16 interaction as a decisive checkpoint in the autophagy-driven PSC activation pathway (reference study).

Comparison with Existing Internal Articles

Multiple internal resources emphasize the importance of reliable models and molecular probes for studying pancreatic fibrosis and gastrointestinal physiology. For example, Ceruletide: Synthetic CCK Analog for Pancreatic Function details the use of ceruletide (SKU B8465) as a robust tool for inducing acute and chronic pancreatitis and for reproducibly modeling fibrotic responses in vivo. Complementing this, ORM2-ZG16 Axis Regulates Pancreatic Fibrosis via Autophagy Control summarizes how ORM2-mediated autophagy inhibition shapes the PSC fibrogenic response. These articles converge on the critical need for both high-fidelity animal models—enabled by agents such as ceruletide—and precise molecular dissection of signaling pathways, as exemplified by the ORM2-ZG16 axis. The synergy between optimized experimental tools and mechanistic insight is fundamental for advancing digestive disorder research.

Limitations and Transferability

Despite its comprehensive experimental design, the study's findings warrant consideration of several limitations. The CP model relies on repetitive ceruletide administration, which, while highly representative, may not encompass all etiological variants of human disease. Although AAV-mediated genetic manipulations provide organ specificity, off-target effects and long-term outcomes remain to be fully elucidated. The translation of ORM2’s regulatory role from murine models to human pathophysiology requires further validation, especially considering the differential expression patterns observed in tissue versus serum. Additionally, the precise molecular mechanism by which ORM2-ZG16 interaction inhibits autophagy downstream of lysosomal fusion remains to be clarified. As such, while the ORM2-ZG16 axis is a promising therapeutic target, its application in clinical interventions or in broader gastrointestinal physiology studies should be approached with measured expectations.

Research Support Resources

For researchers aiming to replicate or extend these findings, validated reagents and protocols are critical. Ceruletide (SKU B8465) from APExBIO is a synthetic decapeptide analog of cholecystokinin (CCK) widely adopted as an inducer of acute and chronic pancreatitis, facilitating reproducible modeling of pancreatic fibrosis and PSC activation. Its solubility profile and high purity make it suitable for gastrointestinal smooth muscle contraction assays and digestive physiology workflows. In combination with genetic and molecular approaches described in the reference study, ceruletide enables rigorous investigation of autophagy modulation and fibrogenic mechanisms in the pancreas. For in-depth technical guidance and troubleshooting, see Ceruletide in Pancreatic Function Research: Protocols & Insights.